| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,715.5 | 1,553.1 |
| Gross profit | 1,346.3 | 1,207.9 |
| Profit before tax | 363.2 | 348.4 |
| Net income | 307.5 | 291.1 |
| EPS (diluted, $ a share) | $0.53 | $0.50 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +5.6% |
|---|---|
| Revenue, year on year | +10.5% |
| Gross margin | 78.5% |
| Operating margin | 17.4% |
10-Q filed with the SEC, NYSE: EW. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Edwards Lifesciences Corp: key numbers
- Share price
- $105.43Close, Nov 17
- Market cap
- $60.6B
- Shares outstanding
- 575MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Edwards Lifesciences Corp
All →Edwards Lifesciences Cvp, Tavr Daniel J. Lippis Sells $64.5K of Stock
Daniel J. Lippis, Cvp, Tavr, sold 619 shares of Edwards Lifesciences Corp at $104.25 a share, worth $64.5K in total on Nov 10, 2026. Shares held after the trade: 40,034 (-1.5%).
- Value
- $64.5K
- Shares
- 619
- Price
- $104.25
- Role
- Cvp, Tavr
- Holding change
- -1.5%
- Trade date
- Nov 10, 2026
Edwards Lifesciences CVP,Strategy/Corp Development Donald E. Bobo Jr. Sells $5.04M of Stock
Donald E. Bobo Jr., CVP,Strategy/Corp Development, sold 48,900 shares of Edwards Lifesciences Corp at $103.05 a share, worth $5.04M in total on Nov 9, 2026. Shares held after the trade: 22,798 (-68.2%).
- Value
- $5.04M
- Shares
- 48,900
- Price
- $103.05
- Role
- CVP,Strategy/Corp Development
- Holding change
- -68.2%
- Trade date
- Nov 9, 2026
Edwards Lifesciences CEO Bernard J. Zovighian Sells $2.38M of Stock
Bernard J. Zovighian, CEO, sold 23,100 shares of Edwards Lifesciences Corp at $102.78 to $103.39 a share (average $103.02) in 2 transactions, worth $2.38M in total on Nov 9, 2026. Shares held after the trade: 98,845 (-12.3%).
- Value
- $2.38M
- Shares
- 23,100
- Average price
- $103.02
- Role
- CEO
- Holding change
- -12.3%
- Trade date
- Nov 9, 2026
Edwards Lifesciences Financial Results
Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, representing 11.2% constant currency growth driven by strong performance in TAVR and TMTT segments. Based on the results, the company raised its full-year 2026 sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97-$3.05.
- Term
- 3 years
“We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook.”
Bernard Zovighian, CEO of Edwards Lifesciences
Edwards Lifesciences Cvp, Tavr Daniel J. Lippis Sells $53K of Stock
Daniel J. Lippis, Cvp, Tavr, sold 619 shares of Edwards Lifesciences Corp at $85.65 a share, worth $53K in total on Oct 8, 2026. Shares held after the trade: 40,034 (-1.5%).
- Value
- $53K
- Shares
- 619
- Price
- $85.65
- Role
- Cvp, Tavr
- Holding change
- -1.5%
- Trade date
- Oct 8, 2026